Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity. Targeted therapies are being investigated as potentially more efficacious and tolerable alternatives for this multiply-relapsing disease. Based on promising activity with rituximab and lenalidomide in previously untre...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood
Autores principales: Ujjani, Chaitra S., Jung, Sin-Ho, Pitcher, Brandelyn, Martin, Peter, Park, Steven I., Blum, Kristie A., Smith, Sonali M., Czuczman, Myron, Davids, Matthew S., Levine, Ellis, Lewis, Lionel D., Smith, Scott E., Bartlett, Nancy L., Leonard, John P., Cheson, Bruce D.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2016
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5123195/
https://ncbi.nlm.nih.gov/pubmed/27697771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-06-718106
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares